Chelsea Counsel Company’s Novartis NVS Stock Holding History

Chelsea Counsel Company’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-19,800	Closed	-$1.73M	–	103
2021 Q4	$1.73M	Hold	19,800	–	–	0.75%	34
2021 Q3	$1.62M	Hold	19,800	–	–	0.74%	35
2021 Q2	$1.81M	Hold	19,800	–	–	0.83%	33
2021 Q1	$1.69M	Hold	19,800	–	–	0.84%	35
2020 Q4	$1.87M	Hold	19,800	–	–	0.96%	31
2020 Q3	$1.72M	Hold	19,800	–	–	1.02%	31
2020 Q2	$1.73M	Hold	19,800	–	–	1.07%	29
2020 Q1	$1.63M	Hold	19,800	–	–	1.28%	26
2019 Q4	$1.88M	Hold	19,800	–	–	1.14%	28
2019 Q3	$1.72M	Hold	19,800	–	–	1.04%	30
2019 Q2	$1.81M	Sell	19,800 -2,297	-10%	-$194K	0.97%	30
2019 Q1	$1.9M	Hold	22,097	–	–	1.03%	29
2018 Q4	$1.7M	Hold	22,097	–	–	1.03%	29
2018 Q3	$1.71M	Hold	22,097	–	–	0.89%	33
2018 Q2	$1.5M	Buy	+22,097	New	+$1.52M	0.89%	35

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Chelsea Counsel Company's NVS Position: Q1 2022 in Review

Chelsea Counsel Company sold out of Novartis (NVS) in Q1 2022, closing a stake of 19,800 shares — an estimated $1.73M sold.

Chelsea Counsel Company first reported a position in NVS in Q2 2018 and held it in 15 quarters. The position peaked at $1.9M in Q1 2019. 1,137 funds tracked by Wall St. Rank hold NVS as of Q1 2022.

Chelsea Counsel Company reported no remaining Novartis position as of Q1 2022 after selling out during the quarter.
Chelsea Counsel Company sold 19,800 Novartis shares in Q1 2022, an estimated $1.73M.
Chelsea Counsel Company first reported a position in Novartis in Q2 2018 and held it in 15 quarters.
Chelsea Counsel Company's Novartis position peaked at $1.9M in Q1 2019.
1,137 funds tracked by Wall St. Rank held Novartis as of Q1 2022.

Based on Chelsea Counsel Company's 13F filing for Q1 2022, filed 24 May 2022.